Published in Int J Cancer on March 20, 2005
Intrinsic molecular signature of breast cancer in a population-based cohort of 412 patients. Breast Cancer Res (2006) 2.69
Gene expression profiling reveals new aspects of PIK3CA mutation in ERalpha-positive breast cancer: major implication of the Wnt signaling pathway. PLoS One (2010) 0.97
O-GlcNAcylation/phosphorylation cycling at Ser10 controls both transcriptional activity and stability of delta-lactoferrin. J Biol Chem (2010) 0.91
Cellular iron metabolism in prognosis and therapy of breast cancer. Crit Rev Oncog (2013) 0.80
Lactoferrin immuno-expression in human normal and neoplastic bone tissue. J Bone Miner Metab (2009) 0.79
Lactoferrin from Milk: Nutraceutical and Pharmacological Properties. Pharmaceuticals (Basel) (2016) 0.78
Genome-wide pathway analysis reveals different signaling pathways between secreted lactoferrin and intracellular delta-lactoferrin. PLoS One (2013) 0.78
Modification by SUMOylation Controls Both the Transcriptional Activity and the Stability of Delta-Lactoferrin. PLoS One (2015) 0.75
Immunoexpression of lactoferrin in triple-negative breast cancer patients: A proposal to select a less aggressive subgroup. Oncol Lett (2017) 0.75
Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients. J Natl Cancer Inst (2002) 2.25
Surface nucleolin participates in both the binding and endocytosis of lactoferrin in target cells. Eur J Biochem (2004) 1.36
Lipomannans, but not lipoarabinomannans, purified from Mycobacterium chelonae and Mycobacterium kansasii induce TNF-alpha and IL-8 secretion by a CD14-toll-like receptor 2-dependent mechanism. J Immunol (2003) 1.25
Lactoferrin structure and functions. Adv Exp Med Biol (2008) 1.22
Syndecan-1/CD147 association is essential for cyclophilin B-induced activation of p44/42 mitogen-activated protein kinases and promotion of cell adhesion and chemotaxis. Glycobiology (2007) 1.21
Contribution of bioinformatics predictions and functional splicing assays to the interpretation of unclassified variants of the BRCA genes. Eur J Hum Genet (2011) 1.16
Epstein-Barr virus (EBV) genome and expression in breast cancer tissue: effect of EBV infection of breast cancer cells on resistance to paclitaxel (Taxol). J Virol (2006) 1.16
Interplay between BRCA1 and RHAMM regulates epithelial apicobasal polarization and may influence risk of breast cancer. PLoS Biol (2011) 1.12
A critical review of the roles of host lactoferrin in immunity. Biometals (2010) 1.05
The heparin/heparan sulfate sequence that interacts with cyclophilin B contains a 3-O-sulfated N-unsubstituted glucosamine residue. J Biol Chem (2007) 1.02
Interactions of lactoferrin with cells involved in immune function. Biochem Cell Biol (2006) 0.99
Mechanisms underlying resistance to cetuximab in the HNSCC cell line: role of AKT inhibition in bypassing this resistance. Int J Oncol (2011) 0.99
Expression of the putative tumor suppressor gene PTPN13/PTPL1 is an independent prognostic marker for overall survival in breast cancer. Int J Cancer (2009) 0.97
Lactoferrin and host defence: an overview of its immuno-modulating and anti-inflammatory properties. Biometals (2004) 0.95
Messenger RNA expression of leptin and leptin receptors and their prognostic value in 322 human primary breast cancers. Clin Cancer Res (2006) 0.95
Association between systemic sclerosis and breast cancer: eight new cases and review of the literature. Clin Rheumatol (2004) 0.94
Multiple sequence variants of BRCA2 exon 7 alter splicing regulation. J Med Genet (2012) 0.94
The cell surface expressed nucleolin is a glycoprotein that triggers calcium entry into mammalian cells. Exp Cell Res (2008) 0.93
Breast cancer risk in BRCA1 and BRCA2 mutation carriers and polyglutamine repeat length in the AIB1 gene. Int J Cancer (2005) 0.91
Mycobacterial lipomannan induces matrix metalloproteinase-9 expression in human macrophagic cells through a Toll-like receptor 1 (TLR1)/TLR2- and CD14-dependent mechanism. Infect Immun (2005) 0.91
O-GlcNAcylation/phosphorylation cycling at Ser10 controls both transcriptional activity and stability of delta-lactoferrin. J Biol Chem (2010) 0.91
mRNA expression of the type I growth factor receptors in the human breast cancer cells MCF-7: regulation by estradiol and tamoxifen. Anticancer Res (2003) 0.90
No association of TGFB1 L10P genotypes and breast cancer risk in BRCA1 and BRCA2 mutation carriers: a multi-center cohort study. Breast Cancer Res Treat (2008) 0.90
Radical fimbriectomy: a reasonable temporary risk-reducing surgery for selected women with a germ line mutation of BRCA 1 or 2 genes? Rationale and preliminary development. Gynecol Oncol (2011) 0.89
High STAT1 mRNA levels but not its tyrosine phosphorylation are associated with macrophage infiltration and bad prognosis in breast cancer. BMC Cancer (2014) 0.89
Cross-talk between mesenchyme and epithelium increases H19 gene expression during scattering and morphogenesis of epithelial cells. Exp Cell Res (2002) 0.88
Octasaccharide is the minimal length unit required for efficient binding of cyclophilin B to heparin and cell surface heparan sulphate. Biochem J (2004) 0.88
Cyclophilin B induces integrin-mediated cell adhesion by a mechanism involving CD98-dependent activation of protein kinase C-delta and p44/42 mitogen-activated protein kinases. Exp Cell Res (2007) 0.88
Lactoferrin inhibits the lipopolysaccharide-induced expression and proteoglycan-binding ability of interleukin-8 in human endothelial cells. Infect Immun (2002) 0.88
Progesterone inhibits human breast cancer cell growth through transcriptional upregulation of the cyclin-dependent kinase inhibitor p27Kip1 gene. FEBS Lett (2005) 0.87
Prognostic value of ERM gene expression in human primary breast cancers. Clin Cancer Res (2004) 0.87
Pooled analysis of prognostic impact of uPA and PAI-1 in breast cancer patients. Thromb Haemost (2003) 0.87
TReP-132 is a novel progesterone receptor coactivator required for the inhibition of breast cancer cell growth and enhancement of differentiation by progesterone. Mol Cell Biol (2006) 0.86
Human delta-lactoferrin is a transcription factor that enhances Skp1 (S-phase kinase-associated protein) gene expression. FEBS J (2007) 0.86
Common BRCA2 variants and modification of breast and ovarian cancer risk in BRCA1 mutation carriers. Cancer Epidemiol Biomarkers Prev (2005) 0.86
Ca2+ modulation of volume-regulated anion channels: evidence for colocalization with store-operated channels. FASEB J (2001) 0.86
Nucleolin undergoes partial N- and O-glycosylations in the extranuclear cell compartment. Biochemistry (2005) 0.85
Binding of Toxoplasma gondii glycosylphosphatidylinositols to galectin-3 is required for their recognition by macrophages. J Biol Chem (2010) 0.85
Multiplex single-nucleotide primer extension analysis to simultaneously detect eleven BRCA1 mutations in breast cancer families. Clin Chem (2004) 0.82
Delta-lactoferrin, an intracellular lactoferrin isoform that acts as a transcription factor. Biochem Cell Biol (2012) 0.82
Mycobacterial lipomannan induces MAP kinase phosphatase-1 expression in macrophages. FEBS Lett (2008) 0.81
Expression of delta-lactoferrin induces cell cycle arrest. Biometals (2004) 0.81
Intestinal colonization with bifidobacteria affects the expression of galectins in extraintestinal organs. FEMS Immunol Med Microbiol (2008) 0.81
N-Glycosylation influences the structure and self-association abilities of recombinant nucleolin. FEBS J (2011) 0.81
[Lactoferrin: a multifunctional protein]. Med Sci (Paris) (2009) 0.80
Proteomic approach to the identification of novel delta-lactoferrin target genes: Characterization of DcpS, an mRNA scavenger decapping enzyme. Biochimie (2008) 0.80
Detection and identification of O-GlcNAcylated proteins by proteomic approaches. Proteomics (2015) 0.80
Purification and structural characterization of de-N-acetylated form of GD3 ganglioside present in human melanoma tumors. Glycobiology (2007) 0.80
TReP-132 controls cell proliferation by regulating the expression of the cyclin-dependent kinase inhibitors p21WAF1/Cip1 and p27Kip1. Mol Cell Biol (2005) 0.80
BRCA1 wild-type allele modifies risk of ovarian cancer in carriers of BRCA1 germ-line mutations. Cancer Epidemiol Biomarkers Prev (2003) 0.79
Synthesis of heparan sulfate with cyclophilin B-binding properties is determined by cell type-specific expression of sulfotransferases. J Biol Chem (2009) 0.79
Relationships between progesterone receptor isoforms and the HER/ErbB receptors and ligands network in 299 primary breast cancers. Int J Biol Markers (2012) 0.79
Identification by surface plasmon resonance of the mycobacterial lipomannan and lipoarabinomannan domains involved in binding to CD14 and LPS-binding protein. FEBS Lett (2007) 0.79
Exploring the link between MORF4L1 and risk of breast cancer. Breast Cancer Res (2011) 0.79
E-selectin gene S128R polymorphism is associated with poor prognosis in patients with stage II or III colorectal cancer. Eur J Cancer (2009) 0.79
Delta-lactoferrin induces cell death via the mitochondrial death signaling pathway by upregulating bax expression. Biometals (2014) 0.77
Discrimination and evaluation of lactoferrin and delta-lactoferrin gene expression levels in cancer cells and under inflammatory stimuli using TaqMan real-time PCR. Biometals (2010) 0.77
Multiplex reverse transcription polymerase chain reaction assessment of sialyltransferase expression in peripheral blood mononuclear cells in systemic sclerosis. J Rheumatol (2004) 0.77
Advances in lactoferrin research. Biochimie (2008) 0.76
Involvement of GAGs in the activity of pro-inflammatory factors. Adv Exp Med Biol (2003) 0.75
Comparison of the screening practices of unaffected noncarriers under 40 and between 40 and 49 in BRCA1/2 families. J Genet Couns (2013) 0.75
Construction of a multi-functional helper-dependent adenovirus based system for cancer gene therapy. Asian Pac J Cancer Prev (2009) 0.75
[Inhibitors of epidermal growth factor receptor and colorectal cancer]. Bull Cancer (2003) 0.75
[Screening pelvic tumours for hereditary risk of ovarian neoplasms, a cancer center experience]. Bull Cancer (2011) 0.75